Planet Briefing

First published · Last updated

O2-1 Nivolumab + ipilimumab versus chemotherapy in MSI-H/dMMR metastatic colorectal cancer: CheckMate 8HW Asian subgroup analysis

Journal article reporting an Asian subgroup analysis of CheckMate 8HW comparing nivolumab plus ipilimumab versus chemotherapy in MSI-H/dMMR metastatic colorectal cancer. Publisher listed as Elsevier BV with publication date 2025-10-01.

Immunotherapy + Durvalumab + Pembrolizumab + Ipilimumab + Atezolizumab mechanism of action
Illustrative image: Immunotherapy + Durvalumab + Pembrolizumab + Ipilimumab + Atezolizumab mechanism of action — Nicola J. Nasser, Miguel Gorenberg, Abed Agbarya 3ORCID/Wikimedia Commons, CC BY-SA 4.0

Categories: public-health, science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence
4/10
Geographic reach
6/10
Global importance
3/10
Impact magnitude
3/10
Positivity
5/10
Urgency
2/10

Why it matters

This article presents a clinical subgroup comparison of immunotherapy versus chemotherapy for MSI-H/dMMR metastatic colorectal cancer in Asian patients.

Sources

Report an issue